Literature DB >> 3619650

Human liver debrisoquine 4-hydroxylase: test for specificity toward various monooxygenase substrates and model of the active site.

T Wolff, L M Distlerath, M T Worthington, F P Guengerich.   

Abstract

Polyclonal antibodies raised toward a debrisoquine 4-hydroxylating cytochrome P-450 species purified from rat liver (P-450UT-A) were used to determine which monooxygenase reactions are linked to debrisoquine hydroxylation in human liver. Anti P-450UT-A did not inhibit the oxidation of dimethylnitrosamine, morphine, diazepam, vinylidene chloride, trichloroethylene, benzo(a)pyrene and its 7.8-dihydrodiol, but was inhibitory for the hydroxylation of debrisoquine, (+/-)-bufuralol, lasiocarpine and monocrotaline. A model interpreting the substrate specificity of the human liver enzyme is presented.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3619650     DOI： 10.1007/bf00296955

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN： 0340-5761            Impact factor:   5.153


  8 in total

Review 1.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

2.  Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.

Authors:  D Larrey; L M Distlerath; G A Dannan; G R Wilkinson; F P Guengerich
Journal:  Biochemistry       Date:  1984-06-05       Impact factor: 3.162

3.  Lack of relationship between debrisoquine 4-hydroxylation and other cytochrome P-450 dependent reactions in rat and human liver.

Authors:  T Wolff; M Strecker
Journal:  Biochem Pharmacol       Date:  1985-08-01       Impact factor: 5.858

4.  Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

Authors:  J Gut; T Catin; P Dayer; T Kronbach; U Zanger; U A Meyer
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

5.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

Authors:  F P Guengerich; L M Distlerath; P E Reilly; T Wolff; T Shimada; D R Umbenhauer; M V Martin
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

6.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.

Authors:  T Wolff; L M Distlerath; M T Worthington; J D Groopman; G J Hammons; F F Kadlubar; R A Prough; M V Martin; F P Guengerich
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

7.  Aldrin epoxidation, a highly sensitive indicator specific for cytochrome P-450-dependent mono-oxygenase activities.

Authors:  T Wolff; E Deml; H Wanders
Journal:  Drug Metab Dispos       Date:  1979 Sep-Oct       Impact factor: 3.922

8.  Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Authors:  L M Distlerath; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205
  8 in total
  1 in total

1.  Polymorphisms in oxidative drug metabolism: relationship to food preference.

Authors:  M R Britto; H E McKean; G G Bruckner; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.